DOW JONES27,081.36-879.44 -3.15%
S&P 5003,128.21-97.68 -3.03%
NASDAQ8,965.61-255.67 -2.77%

Raymond James Maintains Outperform on Haemonetics, Lowers Price Target to $145

Raymond James analyst Lawrence Keusch maintains Haemonetics (NYSE:HAE) with a Outperform and lowers the price target from $150 to $145.

Benzinga · 01/23/2020 12:50

Raymond James analyst Lawrence Keusch maintains Haemonetics (NYSE:HAE) with a Outperform and lowers the price target from $150 to $145.